Abstract:BACKGROUND. Serologic measurement of antibodies to Epstein-Barr virus (EBV) immunoglobulin A/viral capsid antigen (IgA/VCA) and early antigen (IgA/EA) has been used widely to screen for nasopharyngeal carcinoma (NPC) in China. Recently, it was found that plasma EBV DNA concentration is an indicator for the staging and prognosis of patients with NPC. To determine whether there is a correlation between plasma EBV DNA levels and serum levels of IgA/VCA, the authors measured both in patients with NPC and in a control group.METHODS. Real-time polymerase chain reaction was used for quantitative analysis of plasma EBV DNA concentration, and enzyme-linked immunoadsorbent assay was used to measure EBV VCA/IgA in patients with primary NPC (n = 120 patients), locally recurrent NPC (n = 8 patients), and distant metastatic NPC (n = 21 patients) among 76 patients with NPC after the completion of radiotherapy, in 60 patients with NPC in clinical remission, in 38 patients with non-NPC tumors, and in 47 control individuals.RESULTS. The median plasma EBV DNA levels were 6200 copies/mL, 9200 copies/ mL, and 2050 copies/mL in patients with primary, locally recurrent, and distant metastatic NPC, respectively, but declined to 0 copies/mL in patients with clinically remissive NPC, in patients who completed radiotherapy, in patients with non-NPC tumors, and in the control group. In contrast, EBV VCA/IgA titers and detection rates remained high in all NPC groups. Plasma EBV DNA levels were significantly higher in patients who had serum VCA/IgA titers greater than or equal to 1:640 (median, 83,450 copies/mL) compared with the levels in patients who had titers less than or equal to 1:320 (median, 17,200 copies/mL). Patients with NPC who had advanced TNM stage (Stages III and IV; median, 8530 copies/mL) and T classification (T3 and T4 tumors; median, 8530 copies/mL) had significantly higher plasma EBV DNA levels compared with patients who had early TNM stage (Stages I and II; median, 930 copies/mL) and T classification (T1 and T2 tumors; median, 3700 copies). Patients who had advanced TNM stage NPC had significantly higher mean VCA/IgA titers (1:424) compared with patients who had early TNM stage NPC (1:246), but there was no correlation between IgA/VCA titer and T or N classification of NPC.CONCLUSIONS. The results suggest that plasma EBV DNA detection is a more sensitive and specific marker than the serum IgA/VCA titer for the diagnosis and monitoring of patients with NPC. These findings provide convincing evidence for the use of plasma EBV DNA measurements for the early diagnosis and staging of NPC as well as for monitoring recurrence and metastasis of this tumor. (C) 2004 American Cancer Society.

Significance of serum EB-VCA-IgA, EA-D-IgA and EA-D-IgG antibodies in the diagnosis of nasopharyngeal carcinoma

[Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma].

[Assessment of Detection Assays of Epstein-Barr Viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr Viral DNA at Different Clinical Stages in the Diagnosis of Nasopharyngeal Carcinoma].

Application of enzyme-linked immunosorbent assay to the serological diagnosis of nasopharyngeal carcinoma

Diagnosis and prognosis value of EB virus capsid antigen antibody,early antigen antibody,EB - DNA detection on nasopharyngeal carci-noma patients

Serologic Diagnosis of Nasopharyngeal Carcinoma. A Double-Blind Study of Four EB Virus Antibodies with Evaluation by Sequential Discrimination.

The serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis

Correlation study on serum EA-IgA、VCA-IgA、Rta-IgG、EBV-DNA levels of nasopharyngeal carcinoma

Expression of EBV Antibody EA-IgA, Rta-IgG and VCA-IgA and SA in Serum and the Implication of Combined Assay in Nasopharyngeal Carcinoma Diagnosis.

Analysis of serum anti-Epstein-Barr virus antibody in patients with nasopharyngeal carcinoma in Shanghai

Expression of Epstein-Barr virus antibodies EA-IgG, Rta-IgG, and VCA-IgA in nasopharyngeal carcinoma and their use in a combined diagnostic assay.

Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma

Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma.

Ea-D P45-Igg As A Potential Biomarker For Nasopharyngeal Carcinoma Diagnosis

A Diagnostic Test of Optimized Combinations of EBV DNA and EBV Antibodies for Nasopharyngeal Carcinoma

Application of serum nucleobindin-2 in the diagnosis of nasopharyngeal carcinoma

Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-Iga As A Biomarker Panel for the Detection of Nasopharyngeal Carcinoma

Comparison of Plasma Epstein-Barr Virus (ebv) Dna Levels and Serum Ebv Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma

Establishment Of Vca And Ebna1 Iga-Based Combination By Enzyme-Linked Immunosorbent Assay As Preferred Screening Method For Nasopharyngeal Carcinoma: A Two-Stage Design With A Preliminary Performance Study And A Mass Screening In Southern China

Detection of Salivary Epstein-Barr Virus Antibodies for Early Diagnosis of Nasopharyngeal Carcinoma

[Expression and Significance of Serum Sicam-1 and Scd4 & Scd8 in Patients with Nasopharyngeal Carcinoma].